Corticosteroids Market Report 2026

The corticosteroids market size has grown strongly in recent years. It will grow from $5.93 billion in 2025 to $6.33 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rising prevalence of asthma and allergies, established clinical efficacy of corticosteroids, widespread hospital adoption of steroid therapies, increased awareness of inflammatory disease management, expansion of pharmaceutical manufacturing capacity.

The corticosteroids market size is expected to see strong growth in the next few years. It will grow to $8.34 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to growing autoimmune and respiratory disease burden, development of safer steroid formulations, aging global population, rising healthcare access in emerging economies, increased investment in corticosteroid research. Major trends in the forecast period include targeted corticosteroid formulations, low dose and short duration therapies, growth of topical and inhaled corticosteroids, combination therapies with bronchodilators, expanding use in acute respiratory care.

The growing demand for cancer treatment is expected to support the expansion of the corticosteroid market in the coming years. Cancer treatment includes a range of therapeutic approaches such as surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapies, all aimed at eliminating cancer cells and reducing disease-related symptoms. Demand for cancer treatment continues to rise due to factors such as increasing cancer incidence, improved awareness and screening programs, better access to healthcare services, and the availability of supportive care options. Corticosteroids play an important role in cancer care by reducing inflammation, managing treatment-related side effects, and improving patients’ ability to tolerate intensive therapies, which contributes to better overall outcomes. For example, in May 2024, the National Health Service (NHS), the United Kingdom’s healthcare system, reported record-high treatment activity, with more than 1,400 patients beginning cancer treatment each working day. Between April 2023 and March 2024, nearly 340,000 people received their first cancer treatment. As a result, the increasing demand for cancer treatment is driving growth in the corticosteroid market.

Leading companies in the corticosteroids market are focusing on the development of innovative products, such as rescue medications, to expand their customer base, increase sales, and enhance revenue generation. Rescue medications are therapies designed to provide rapid relief from acute or severe symptoms or sudden flare-ups of chronic conditions. For instance, in January 2023, AstraZeneca PLC, a UK-based pharmaceutical company, announced FDA approval for Airsupra (albuterol/budesonide). This product is the first-in-class pressurized metered-dose inhaler (pMDI) combining a short-acting beta2-agonist, albuterol, with budesonide, an inhaled corticosteroid that offers anti-inflammatory effects. Airsupra is indicated for adults aged 18 years and older and can be used as needed for the treatment or prevention of bronchoconstriction, while also helping to reduce the risk of asthma exacerbations. The product is available in the United States and is being developed by AstraZeneca in partnership with Avillion.

In June 2024, Sun Pharmaceutical Industries Ltd., an India-based specialty generic pharmaceutical company, acquired Taro Pharmaceutical Industries Ltd. for an undisclosed amount. This acquisition is intended to strengthen Sun Pharma’s position in the global pharmaceutical market, particularly in off-patent drugs, prescription medicines, and over-the-counter products. Taro Pharmaceutical Industries Ltd. is an Israel-based research-driven pharmaceutical manufacturer with a portfolio that includes corticosteroids.

Major companies operating in the corticosteroids market are McKesson Corporation, Pfizer Inc., Johnson and Johnson Services Inc., Merck & Co.Inc., Bayer AG, Novartis International AG., Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo International plc, Lupin Limited, Mallinckrodt Pharmaceuticals Ltd., LEO Pharma A/S, Glenmark Pharmaceuticals Ltd., Wockhardt Limited, Allergan plc, Hikma Pharmaceuticals pl.

North America was the largest region in the corticosteroids therapy market share in 2025. Middle East is expected to be the largest growing region in the global corticosteroids market during the forecast period. The regions covered in the corticosteroids market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the corticosteroids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the corticosteroids market by increasing the cost of imported active pharmaceutical ingredients and intermediates used in steroid production. This has created pricing pressure for glucocorticoids supplied to hospitals and clinics, especially in regions dependent on cross border pharmaceutical trade such as Asia Pacific and Europe. Respiratory and dermatology applications are among the most affected due to high consumption volumes. At the same time, tariffs are encouraging local manufacturing, supply chain diversification, and improved long term regional production resilience.

The corticosteroids market research report is one of a series of new reports that provides corticosteroids market statistics, including corticosteroids industry global market size, regional shares, competitors with a corticosteroids market share, detailed corticosteroids market segments, market trends and opportunities, and any further data you may need to thrive in the corticosteroids industry. This corticosteroids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Corticosteroids refer to a treatment administered through various methods to suppress the immune system and reduce inflammation. These therapies are used to manage conditions such as asthma and to relieve allergy-related symptoms, including hay fever and urticaria (hives). Corticosteroids, also referred to as steroids, are a class of anti-inflammatory drugs.

The primary product types of corticosteroidinclude glucocorticoids and mineralocorticoids. Glucocorticoids are a category of corticosteroid hormones that are highly effective in immune suppression and inflammation reduction. This therapy is used in the treatment of skin allergies, rheumatologic conditions, endocrinological disorders, and acute respiratory diseases, and is utilized by hospitals, clinics, research institutes, and other healthcare settings.

The corticosteroids therapy market consists of sales of glucocorticoids, mineralocorticoids, cortisone, hydrocortisone, and prednisone. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.